Not medical advice. Talk to your provider before using any peptide. Full disclaimer
PEG-MGF
Beginner tier: 150 mcg, 2x/week · 6w on / 4w off · community consensus
Also known as: PEG-MGF, PEGylated IGF-1Ec, PEGylated MGF E-peptide
Mechanical loading switches on the Mechano Growth Factor splice variant of the IGF-1 gene in muscle [3]. PEG-MGF wraps a synthetic copy of its E-peptide in a polyethylene glycol chain, aiming for an estimated 48 to 72 hour half-life. Kandalla and colleagues found the E-peptide extended the life span of dividing human muscle progenitor cells from young donors, not old ones [1]. Community protocols from peptide forums report reduced DOMS and faster session-to-session recovery by weeks two to three. Dosing runs 150 to 400 mcg, injected two to three times per week post-workout. No human clinical trial has tested PEG-MGF itself; all published data covers native MGF in animal or cell models.
What Is PEG-MGF?
PEG-MGF (PEGylated Mechano Growth Factor, also called PEGylated IGF-1Ec splice variant) is a modified version of a synthetic 24-amino-acid peptide. That peptide copies the last 24 amino acids of the MGF E domain (IGF-1Ec in humans). MGF is an IGF-1 splice variant that muscle expresses more of after mechanical loading [3]. The four references on this page cover native MGF or its E-peptide, not the PEGylated compound. That distinction matters. Native MGF is often quoted at a 5 to 7 minute half-life, but no published study has measured one. The attached PEG chain is meant to shield it from enzymes. The 48 to 72 hour half-life is an estimate from PEGylation principles, not a measurement.
Community use centers on muscle recovery and satellite cell priming. Users inject 150 to 400 mcg subcutaneously or intramuscularly near the trained muscle, two to three times per week after workouts. Most consistent reports describe reduced delayed-onset muscle soreness starting around week two to three. The peptide is often stacked sequentially with IGF-1 LR3, with PEG-MGF running first to expand the satellite cell pool, then IGF-1 LR3 to drive differentiation.
The honest assessment: PEG-MGF sits in a category where the underlying biology is real and the community experience is cautiously positive, but the clinical evidence gap is wider than for most peptides on this platform. Kandalla et al., with Goldspink, saw satellite cell activation in cultured human muscle cells [1]. Qin et al. mapped proliferation without differentiation in cultured porcine satellite cells [2]. A 2010 review by Matheny's group notes that no MGF peptide has been isolated from tissue or blood [3]. None tested the PEGylated form.
How PEG-MGF Works
PEG-MGF binds to receptors on muscle cells through its unique C-terminal E-peptide domain. This binding activates quiescent satellite cells through a pathway largely independent of the classical IGF-1 receptor. The E-peptide down-regulates MyoD and p21, two transcription factors that normally push satellite cells toward terminal differentiation. By suppressing these signals, PEG-MGF keeps satellite cells proliferating without committing to become mature muscle fibers.
This priming phase expands the pool of myogenic precursor cells available for repair. Think of it as building inventory. Once PEG-MGF levels drop after the cycle ends, mature IGF-1 signaling through the PI3K/Akt pathway takes over. That second wave drives the expanded satellite cell pool to differentiate and fuse into existing or new muscle fibers.
The PEG moiety handles the pharmacokinetic problem. Native MGF is described as short-lived, but Goldspink's group gave no number [4]. The polyethylene glycol chain creates a hydration shell that blocks enzyme access. Small PEG chains still clear fast. In mice, a 6 kDa PEG left the blood with an 18-minute half-life [5]. The 48 to 72 hour figure for PEG-MGF is an estimate, not a measurement.
Qin and colleagues mapped this proliferation-without-differentiation pattern in cultured porcine satellite cells [2]. Cultured human muscle cells in Kandalla's study [1] showed a similar activation signal. Neither study tested the PEGylated version directly.
PEG-MGF Benefits
- PEG-MGF benefits center on satellite cell activation and post-workout recovery, with the strongest community signal in DOMS reduction.
- Satellite cell proliferation without premature differentiation is the proposed core mechanism. In cultured porcine satellite cells, MGF boosted proliferation while blocking differentiation [2]; PEG-MGF itself is untested.
- An estimated PEGylated half-life of 48 to 72 hours is why community protocols dose twice weekly. That figure has never been measured.
- Community users consistently report reduced DOMS and faster session-to-session recovery starting around weeks two to three, based on 50 to 150 threads across r/peptides and peptide forums.
- Localized injection near the trained muscle allows site-specific satellite cell activation. Intramuscular delivery maximizes paracrine exposure at the exact tissue that experienced mechanical damage.
- Sequential stacking with IGF-1 LR3 covers both phases of muscle regeneration. PEG-MGF handles proliferation; IGF-1 LR3 drives differentiation and fusion into mature fibers.
PEG-MGF: Science vs Community Consensus
Zero peer-reviewed studies exist for the bodybuilding PEGylated compound specifically.
Read the evidence (key study, limitations)
All evidence is extrapolated from native MGF / MGF-E peptide animal and cell studies. PEGylation pharmacokinetics (48–72h half-life) are estimated from first principles, not measured. No formal human clinical trials have been completed for PEG-MGF. Human efficacy is entirely unproven.
Kandalla PK et al. 2011, Mech Ageing Dev (PMID 21354439): MGF E-peptide lengthened the proliferative life span of human muscle cells from young donors, not old ones. Cited as most relevant positive result but studies native MGF, not PEGylated form.
No human RCTs or PK studies for PEG-MGF specifically. All 4 cited references examine native MGF or MGF-E peptide in animal/cell models. The 48–72h half-life is an estimate extrapolated from PEGylation principles. Anti-PEG antibody formation risk is undocumented for this compound but is a class risk. Body of evidence does not support any efficacy claim in humans.
Cautiously positive for recovery enhancement and DOMS reduction; skeptical for direct mass-building effects.
Read the reports (what users report 5, common issues 5)
Valued over native MGF for practical twice-weekly dosing. Commonly used as a recovery layer within GH secretagogue stacks.
- Practical twice-weekly dosing vs gym-floor immediacy required for native MGF
- Reduced DOMS and faster session-to-session recovery (anecdotal, weeks 2–3)
- Localized hypertrophy potential when injected near trained muscle (IM)
- Satellite cell priming: reported improved training frequency and capacity
- Complements IGF-1 LR3 when used sequentially (proliferation → differentiation)
- Subtle effects compared to IGF-1 LR3: commonly described as "recovery enhancer, not mass builder"
- Inconsistent purity across gray-market research products: quality risk is high
- Cost relative to perceived benefit vs cheaper BPC-157 for recovery
- Theoretical anti-PEG antibody formation risk with long-term or repeated cycles
- No human data to calibrate dose or validate satellite cell mechanism in vivo
Community use is based entirely on extrapolation from native MGF animal data and PEGylation pharmacokinetic principles. No human study, positive or negative, of PEGylated MGF has been published. Community reports modest recovery benefit, but no scientific evidence (positive or negative) exists for this specific compound to align or diverge from. Classified science-only to reflect that any alignment assessment is based on indirect inference, not actual data.
PEG-MGF Dosage Guide
Reconstitution math for a 2 mg vial with 1 mL bacteriostatic water: total volume is 100 units on an insulin syringe, each unit delivers 20 mcg. So 150 mcg is 7.5 units, 200 mcg is 10 units, 400 mcg is 20 units. For a 5 mg vial with 1 mL bacteriostatic water: each unit delivers 50 mcg. That puts 150 mcg at 3 units, 200 mcg at 4 units, 400 mcg at 8 units.
Start at the beginner dose (150 mcg, 2 times per week) even if you've used other peptides before. PEG-MGF has zero human dose-response data; the community arrived at these numbers by trial and error over years, not from clinical guidance.
Inject post-workout, within 30 minutes of finishing your session. The satellite cell activation window overlaps with the mechanical damage signal your muscles are already producing. For bilateral muscle groups (quads, pecs), split the dose between both sides. A single-site injection for bilateral training misses half the target tissue.
Don't combine PEG-MGF and IGF-1 LR3 in the same injection window. Stagger them by at least 4 to 6 hours. Both compete for satellite cell receptor binding, and concurrent dosing may negate the proliferation phase.
Store reconstituted vials at 2 to 8 degrees Celsius. Use within 3 to 4 weeks. Discard if the solution turns cloudy or contains visible particles.
Cycling Protocol
Cycle to prevent receptor desensitization. Most protocols use 4-8 weeks on, 2-4 weeks off. Inject on training days within 30 minutes post-workout for optimal satellite cell activation.
Community protocols cycle 4–6 weeks on / 4 weeks off based on presumed receptor accommodation within IGF-1/satellite cell pathways and to mitigate theoretical anti-PEG antibody formation risk. No human receptor desensitization data exists specifically for PEG-MGF. Cycling also limits continuous mitogenic signaling, which is prudent given the complete absence of long-term safety data in humans.
- Diminishing recovery improvement during the cycle: DOMS reduction fades after week 3–4
- Reduced muscle fullness or no further improvement in training capacity past week 4
- Increasing injection site irritation, systemic fatigue, or unexplained inflammation over successive cycles
- Possible anti-PEG immune response: injection site reactions worsening over time rather than improving
Or use the universal Peptide Calculator for any peptide.
PEG-MGF Protocols by Goal
Expected: Modest DOMS reduction and recovery improvement (anecdotal; no controlled human data). No acute anabolic effect expected at this dose.
Monitor: Check blood glucose at baseline and day 7. Inspect injection sites before each use.
How to Use PEG-MGF
- 1Step 1
Gather supplies: PEG-MGF vial (2 mg or 5 mg lyophilized), bacteriostatic water, alcohol swabs, 29 to 31 gauge insulin syringe (0.5 mL or 1 mL).
- 2Step 2
Reconstitute by adding 1 mL of bacteriostatic water to the vial. Direct the stream against the glass wall, not onto the powder. Swirl gently until dissolved. Do not shake. For a 2 mg vial, this gives 20 mcg per unit. For a 5 mg vial, 50 mcg per unit.
- 3Draw your dose
Using a 2 mg vial with 1 mL BAC water: beginner 150 mcg = 7.5 units, moderate 200 mcg = 10 units, aggressive 400 mcg = 20 units. Using a 5 mg vial: 150 mcg = 3 units, 200 mcg = 4 units, 400 mcg = 8 units.
- 4Clean the injection site with an alcohol swab
For subcutaneous injection, pinch a fold of skin on the abdomen or outer thigh and insert at a 45 degree angle. For intramuscular injection near the trained muscle, insert at a 90 degree angle into the target area.
- 5Inject slowly and hold for 5 seconds before withdrawing
For bilateral muscle groups, split the dose between both sides (e.g., 100 mcg per quad for a 200 mcg dose).
- 6Step 6
Timing is post-workout, within 30 minutes of finishing your session. Inject on training days only, 2 to 3 times per week depending on your dosing tier.
- 7Step 7
Store the reconstituted vial in the refrigerator at 2 to 8 degrees Celsius. Use within 3 to 4 weeks. Lyophilized (unreconstituted) vials store at 2 to 8 degrees Celsius for up to 12 months, or at minus 20 degrees Celsius for longer-term storage.
Alternative Routes
Standard community dose 150–400 mcg per injection
IM injection near the trained muscle maximizes potential satellite cell exposure at the site of mechanical damage. Split dose bilaterally for paired muscle groups (quads, pecs, biceps). Unlike native MGF, the 48–72h half-life allows some systemic distribution even from IM dosing.
Same dose range; site-specific localized effect may be reduced vs IM
The extended half-life makes SC dosing significantly more practical than for native MGF: systemic PEG-MGF exposure and satellite cell activation occurs. Community commonly uses SC abdominal injection. Localized muscle-specific effect is likely reduced vs IM, but systemic satellite cell priming still occurs.
PEG-MGF Stacking Protocols
Works With
PEG-MGF drives satellite cell proliferation without differentiation; IGF-1 LR3 drives the full PI3K/Akt/mTOR differentiation cascade. Sequential use covers both phases of muscle regeneration.
PEG-MGF 200–400 mcg 3×/week post-workout × 4–6 weeks → switch to IGF-1 LR3 50–100 mcg once daily × 4 weeks. Stagger by ≥4–6h if used on same training days: do NOT co-administer in the same injection window.
BPC-157 addresses connective tissue, gut, and systemic healing via nitric oxide pathways. PEG-MGF targets satellite cell activation. Combined for injury recovery protocols: complementary mechanisms with no documented interaction.
BPC-157 250–500 mcg/day SC + PEG-MGF 200 mcg 2–3×/week post-workout × 4–6 weeks
TB-500 promotes actin dynamics, angiogenesis, and progenitor cell migration systemically. PEG-MGF activates muscle satellite cells locally. Combined for injury recovery and muscle repair.
TB-500 2–5 mg SC 2×/week + PEG-MGF 200 mcg 2–3×/week post-workout × 4–6 weeks
Ipamorelin stimulates pulsatile GH release upstream; PEG-MGF acts downstream at the satellite cell level. Community uses GH secretagogues as a foundation with PEG-MGF to maximize the muscle repair and growth environment.
Ipamorelin 200–300 mcg SC 3×/day + PEG-MGF 200 mcg post-workout 3×/week; ipamorelin continues through PEG-MGF on and off phases.
Avoid
Simultaneous dosing in the same injection window may cause receptor competition at the satellite cell level. Separate by ≥4–6 hours or run in alternating cycles. Sequential use is a validated community stack: this is a timing precaution, not an absolute contraindication.
PEG-MGF carries an independent hypoglycemia risk via IGF-1 pathway activation. Combining with exogenous insulin or insulin secretagogues produces additive glucose-lowering effects. Avoid co-administration unless under medical supervision with active glucose monitoring.
Do not combineGlucocorticoids impair satellite cell activation and antagonize myogenic pathways, significantly reducing expected PEG-MGF benefit.
Estimated Cost
Pricing updated 2026-04-09
PEG-MGF Side Effects
The biggest concern with PEG-MGF is the complete absence of human safety data. No clinical trial, no pharmacokinetic study, and no toxicology profile has been conducted on this specific compound in humans. Every safety assessment is borrowed from native MGF animal research, PEGylation class effects, and community self-reports. That isn't a reason to panic, but it means you're working without guardrails that exist for better-studied peptides.
Cancer risk deserves attention first. PEG-MGF activates satellite cell proliferation through IGF-1 pathway signaling. Any compound that stimulates cell division carries a theoretical mitogenic risk. The peptide is contraindicated for anyone with active malignancy, a history of cancer, or pre-existing musculoskeletal tumors. This isn't a soft warning.
Hypoglycemia is the most commonly reported acute side effect at higher doses. PEG-MGF activates the IGF-1 pathway, which has independent glucose-lowering activity. Symptoms include shakiness, sweating, and post-injection fatigue. This risk compounds when stacking with IGF-1 LR3 or exogenous insulin. Monitor fasting blood glucose at baseline, at day 7, and at the end of each cycle.
Injection site reactions (pain, redness, swelling) are standard for a peptide administered subcutaneously or intramuscularly. These tend to be worse during the first week and settle as technique improves and sites are rotated.
Water retention and joint discomfort show up in community reports, typically at moderate-to-aggressive doses. Localized muscle tightness or cramping near the injection site is reported during the first two weeks. Blood pressure changes appear occasionally but without a clear pattern.
Anti-PEG antibody formation is the long-term unknown. Other PEGylated drugs, including pegfilgrastim and PEGylated asparaginase, have triggered anti-PEG immune responses in clinical use. Nobody has studied this for PEG-MGF specifically. Worsening injection site reactions across successive cycles, rather than improving tolerance, may signal antibody formation. Cycling off for four or more weeks between courses is the community's precautionary approach.
Contraindications: active malignancy or cancer history, pregnancy or breastfeeding (zero safety data), active intracranial lesions or pituitary tumors, uncontrolled diabetes or severe hypoglycemia risk, severe hepatic or renal impairment, known hypersensitivity to PEGylated compounds, pre-existing musculoskeletal tumors. Stop immediately and seek medical attention if you experience signs of hypoglycemia, infection at the injection site, or worsening reactions across cycles.
Common Issues & Solutions
If no recovery improvement by week 3, reassess injection route: SC abdominal delivery for this localized peptide may reduce site-specific effect; switch to IM near the trained muscle.
If using IGF-1 LR3 on the same training days, ensure ≥4–6 hour separation: concurrent dosing risks receptor competition and negates the proliferation phase.
If experiencing hypoglycemia symptoms (shakiness, sweating, fatigue post-injection), reduce dose by 25% or inject after a carbohydrate-containing meal rather than fasted.
If injecting bilaterally (quads, pecs), split the dose between both sides: single-site injection for bilateral training likely misses one side and creates asymmetric stimulus.
If the cycle benefit fades earlier than expected (week 3 vs week 6), consider antibody formation or product degradation: extend the off-cycle to 6+ weeks; a fresh lot with a current COA helps rule out degradation.
Ask AI about this page
Ask AI for a second opinion on PEG-MGF dosing and side effects
Contraindications
- Active malignancy or history of cancer (satellite cell stimulation may promote tumor growth)
- Pregnancy or breastfeeding (no safety data available)
- Active intracranial lesions or pituitary tumors
- Uncontrolled diabetes or severe hypoglycemia risk
- Severe hepatic or renal impairment (affects PEG-MGF metabolism and clearance)
- Known hypersensitivity to PEGylated compounds or MGF peptides
- Pre-existing musculoskeletal tumors or abnormal tissue growth
Drug Interactions
- IGF-1 LR3: avoid simultaneous dosing; stagger by 4-6 hours to prevent receptor competition and allow sequential satellite cell activation then differentiation
- Exogenous growth hormone (HGH): may amplify IGF-1 axis stimulation; monitor for excessive growth factor activity
- Insulin: combined hypoglycemia risk; monitor blood glucose closely if co-administering
- Glucocorticoids (prednisone, dexamethasone): may impair satellite cell activation and blunt PEG-MGF efficacy
- Somatostatin analogs (octreotide): may suppress downstream GH/IGF-1 signaling and reduce complementary effects
Product Quality
Research-grade only: no pharmaceutical manufacturing standards apply. PEGylation adds complexity; confirming intact PEG-peptide conjugation requires mass spectrometry beyond basic HPLC purity testing. No regulatory oversight. Community reports inconsistent purity across products. Anti-PEG immune response risk is elevated with lower-purity batches containing free PEG fragments.
- COA benchmark: third-party HPLC purity ≥98% AND mass spectrometry (MS) confirmation of intact PEGylated peptide, in addition to free peptide purity.
- Cold-pack shipping is critical: heat can degrade the PEG-peptide bond, so product shipped without a cold chain may arrive degraded.
- Store lyophilized at 2–8°C (up to 12 months) or −20°C (long-term). Avoid repeated freeze-thaw cycles.
- Once reconstituted, use within 3–4 weeks at 2–8°C; discard if solution is cloudy or contains visible particulate matter.
- Only publicly posted lot-specific third-party test results document a batch; a generic batch certificate does not.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Fasting blood glucose | Baseline before starting; recheck at day 7 and end of each cycle | 70–100 mg/dL fasting |
| Injection site inspection | Before each injection session | Not listed |
| Serum IGF-1 | Optional: baseline and end of cycle: particularly if stacking with IGF-1 LR3 or GH secretagogues | Age-adjusted normal range (typically 115–307 ng/mL for adults) |
PEG-MGF activates the IGF-1 pathway and carries an independent hypoglycemia risk, especially at higher doses or when stacked with other IGF pathway peptides.
Repeated SC or IM injections risk infection, granuloma, nodule formation, or abscess: particularly with IM site-specific protocols.
Compound IGF-1 pathway stimulation from PEG-MGF + IGF-1 LR3 + GH secretagogue can compound pathway exposure beyond expected single-agent levels.
PEG-MGF Before and After
Satellite cell activation begins. Mild injection site reactions may occur. Improved subjective recovery from workouts reported by some users. No visible changes yet.
Noticeable reduction in delayed-onset muscle soreness (DOMS). Training capacity may increase as recovery improves. Early gains in muscle fullness reported.
Peak effects on muscle repair and growth become apparent. Measurable improvements in recovery time between sessions. Increased muscle density and hardness reported.
Receptor sensitivity reset period. Satellite cell pool remains expanded from the on-cycle priming. Maintain training stimulus to retain gains. Transition to other peptides if desired.
What to Expect
Days 1 to 7 (Injection Site Adaptation): No measurable anabolic changes during this phase. PEG-MGF begins reaching satellite cells, but proliferation takes days to initiate at the cellular level. Expect mild injection site redness and swelling, especially if you're new to intramuscular or subcutaneous peptide injections. Some users report a subtle reduction in post-workout fatigue by day 5 to 7, though this is difficult to separate from placebo at such an early stage.
Weeks 2 to 3 (Recovery Improvement Window): This is the most consistent benefit period based on community reports. DOMS drops noticeably, and session-to-session recovery feels faster. Training frequency often increases because soreness no longer forces extra rest days. The cited MGF work used cultured human muscle cells, not trained muscle [1]. Whether PEG-MGF keeps any signal going between doses is untested. Localized muscle tightness or fullness at injection sites is common. Some users report mild joint stiffness.
Weeks 4 to 6 (Peak Satellite Cell Priming): Increased muscle fullness and density are reported during this window. Extrapolating from animal data, the satellite cell pool should be meaningfully expanded by this phase. Recovery benefits may plateau or show diminishing returns past week 4. That pattern is consistent with receptor accommodation or early anti-PEG antibody formation. If effects fade noticeably before week 6, extending the upcoming off-cycle to 6 or more weeks is worth considering.
Off-cycle, Weeks 7 and Beyond (Receptor Reset and Gain Retention): The expanded satellite cell pool persists after PEG-MGF clears. Continued training converts those progenitor cells into new myonuclei, the permanent markers of muscle adaptation. No human data on withdrawal effects or rebound exists. Community users who transition into an IGF-1 LR3 phase (50 to 100 mcg daily for 4 weeks) after PEG-MGF report better gain retention than PEG-MGF alone. Maintain training stimulus and adequate protein intake (1.8 g/kg/day minimum) to retain what the cycle built.
Detailed Timeline: Science vs Community
No measurable anabolic changes. PEG-MGF begins reaching satellite cells, but proliferation takes days to initiate.
Mild injection site redness and swelling common for first-time users. Some report subjective fatigue reduction by day 5–7.
No human clinical timeline data. The MGF E-peptide work used cultured human muscle cells (PMID 21354439). Whether PEG-MGF's estimated 48–72h half-life sustains a signal in muscle is untested.
Most consistent benefit period: DOMS noticeably reduced, session-to-session recovery faster. Anecdotal improvement in training frequency.
No human clinical endpoint data. Extrapolating from animal models: satellite cell pool should be meaningfully expanded by this phase.
Increased muscle fullness and density reported. Recovery benefit may plateau. Some users note diminishing returns past week 4: consistent with receptor accommodation or antibody formation.
Receptor sensitivity normalization period. Satellite cell pool remains expanded; training converts expanded pool into new myonuclei. No human withdrawal or rebound data.
Benefits largely maintained with continued training stimulus and adequate nutrition. Sequential IGF-1 LR3 users report better retention than PEG-MGF alone.
Pharmacokinetics
Source: Estimated from PEGylation principles, not measured. No published PK study of MGF or PEG-MGF exists in any species (PubMed search), and FDA found no human exposure data for PEG-MGF.
Pharmacokinetics: Active Dose Over Time
t½ = ~48-72 hours (PEGylated, estimated, never measured)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is PEG-MGF Legal?
PEG-MGF has no FDA approval for any indication. It carries a research-only regulatory status. No clinical trial has been registered for this compound, and no pharmaceutical manufacturer produces it under GMP conditions. The peptide is sold online labeled "for research purposes only" or "not for human consumption."
Quality control is a particular concern with PEG-MGF. Confirming intact PEGylation requires mass spectrometry beyond standard HPLC purity testing. Community reports flag inconsistent purity across products. Only lot-specific third-party certificates of analysis with both HPLC and mass spectrometry results confirm what a vial contains.
FDA moved PEG-MGF out of 503A category 2 on Apr 22, 2026, after its nominator withdrew it. That does not make it eligible for compounding, because it is not on the 503A bulks list. FDA says it plans to consult its compounding advisory committee on PEG-MGF before the end of February 2027.
Athletes subject to drug testing should treat this as prohibited. WADA's 2026 Prohibited List names mechano growth factors (MGFs) under S2.3, banned in and out of competition.
This content is for educational and informational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any peptide.
Evidence grade: No human studies found (Peptide Evidence Gap, October 2026)
Who Should Consider PEG-MGF
- Athletes and bodybuilders seeking enhanced muscle recovery and hypertrophy
- Individuals recovering from exercise-induced or mechanical muscle damage
- Researchers studying satellite cell biology and muscle regeneration
- Adults interested in body recomposition with targeted muscle growth
- Users of GH secretagogue stacks looking to add a direct myogenic peptide
Related Peptides
What Changed for PEG-MGF
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, Melanotan II
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Dates to watch
- Committee review
FDA intends to consult its compounding advisory committee on adding these peptides to the 503A bulks list, per FDA.
What this does not mean: No meeting date is set yet. A committee vote is advice to FDA, not a rule; the 503A bulks list changes only through notice-and-comment rulemaking.
Also covers: LL-37, GHK-Cu, Dihexa, Melanotan II
Peptide Schedule Research TeamReviewed Apr 7, 20266 Citations
References
- [1]Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages (Kandalla et al., Mech Ageing Dev 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Mechano growth factor (MGF) promotes proliferation and inhibits differentiation of porcine satellite cells (PSCs) by down-regulation of key myogenic transcriptional factors (Qin et al., Mol Cell Biochem 2012) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration (Matheny, Nindl and Adamo, Endocrinology 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Effects of activity on growth factor expression (Int J Sport Nutr Exerc Metab 2001) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice (J Pharm Sci 1994) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is PEG-MGF?
Niche. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 50–150. Community mentions on Reddit: ~50–150 threads estimated.
4 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Moderate search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.